SB-01peptidefor sale The SB-01 peptide, also known as Vicatertide, is a synthetic seven-amino acid peptide developed to target and inhibit Transforming Growth Factor Beta (TGF-β). TGF-β is a pleiotropic cytokine found in nearly all tissues, playing a significant role in cellular processes such as cell growth, differentiation, and immune responseSpine BioPharma and Ensol BioSciences to Expand SB-01 .... In conditions like Degenerative Disc Disease (DDD), elevated levels of TGF-β are implicated in inflammation and tissue damage, contributing to chronic low back pain. Consequently, SB-01's mechanism of action is centered on antagonizing TGF-β activity, with the aim of reducing inflammation and potentially supporting tissue repair in conditions like DDD.
Spine BioPharma has been a primary developer of SB-01, investigating its potential for treating chronic low back pain associated with DDD. The peptide is formulated for injection directly into the spinal disc, positioning it as a potential first-in-class intradiscal pharmacologic treatment for this condition. The company has conducted extensive clinical trials, including the Phase III MODEL trial, to assess the safety and effectiveness of SB-01 for Injection.SB 01 is a synthetic peptidehaving 7-amino acid acting as a transforming growth factor beta (TGFβ) receptor antagonist, being developed by Spine Biopharma, ... These trials have focused on participants experiencing chronic low back pain and related disability due to DDD. While clinical trial results have indicated numerical and clinically meaningful improvements in some patients, the primary endpoints of certain trials have not always been met, highlighting the complexities of treating chronic pain conditionsEmerging Use of BPC-157 in Orthopaedic Sports Medicine - PMC.
The core of SB-01's therapeutic potential lies in its ability to bind to and antagonize TGF-β.Spine BioPharma concludes enrolment in Phase III back ... By inhibiting TGF-β signaling pathways, SB-01 aims to counteract the pro-inflammatory and tissue-remodeling effects that contribute to the pathology of DDD. Transforming Growth Factor Beta 1 (TGF-β1) is a specific isoform often implicated in these disease processes2025年8月4日—Known also as Remedisc or vicatertide,SB-01 is a synthetic 7-amino acid peptidedesigned to target transforming growth factor beta 1, or TGFβ1, .... Therefore, SB-01's design as a TGF-β1 inhibitor is crucial for its intended therapeutic outcome: reducing inflammation within the spinal disc and thereby alleviating associated pain and disability.
Spine BioPharma's clinical development program for SB-01 has involved multiple phases, including significant Phase III studies. The MODEL trial, for instance, was designed to confirm the safety and effectiveness of SB-01 for Injection in adult patients with chronic low back pain linked to DDD. While recent topline results from the Phase III MODEL trial indicated that the study did not achieve its primary goal, it's important to note that SB-01 has demonstrated durable clinical improvements and consistent results in some patient cohorts. This suggests that while the overall trial outcome may not have met its stringent primary endpoint, the peptide may still offer benefits for certain individuals. Further analysis of trial data and ongoing research will be critical in understanding the full therapeutic profile of SB-01 and its potential future applications. The peptide's development also involves collaborations, such as the one between Spine BioPharma and Ensol BioSciences, aimed at expanding its development and potential reach2025年8月4日—Spine BioPharma's Phase III MODEL trial assessing SB-01for people with CLBP associated with DDD failed to achieve its primary goal..
While SB-01 is a prominent peptide in the context of TGF-β inhibition and DDD, other peptides are also being explored for various therapeutic applications.SB-01 is a synthetic peptide that modulates TGF-Beta activity, offering a potential non-surgical treatment option for DDD-related pain. Spine BioPharmaSearch ... For instance, SBP1, a 23-amino acid fragment derived from the ACE2 peptidase domain, is being studied for its role in interactions with the SARS-CoV-2 receptor. Additionally, research into peptides like BPC-157, which has shown promise in orthopaedic sports medicine, and the study of myelin basic protein fragments, like MBP-B MHC II DRB1*15:01, highlight the diverse and evolving landscape of peptide researchMBP-B MHC II DRB1*15:01 (84-102). These related areas, while distinct from SB-01's primary focus, underscore the broad potential of peptides in addressing a wide range of biological and medical challenges.
The SB-01 peptide, or Vicatertide, represents a targeted approach to managing the pain and inflammation associated with Degenerative Disc Disease by inhibiting the TGF-β pathwaySpine BioPharma and Ensol BioSciences to Expand SB-01 .... Developed by Spine BioPharma, its journey through clinical trials, including the Phase III MODEL trial, has provided valuable insights into its efficacy and potential benefits, despite some challenges in meeting primary endpoints. The peptide's specific mechanism of action as a seven-amino acid synthetic TGF-β inhibitor positions it as a significant development in the search for non-surgical treatments for chronic low back pain. Continued research and analysis of clinical data will shape the future understanding and application of SB-01 in the medical field.
Join the newsletter to receive news, updates, new products and freebies in your inbox.